Back to Journals » OncoTargets and Therapy » Volume 6
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
Authors Terpos E , Kanellias N, Christoulas D, Kastritis E , Dimopoulos MA
Received 18 January 2013
Accepted for publication 20 March 2013
Published 10 May 2013 Volume 2013:6 Pages 531—538
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Evangelos Terpos, Nikolaos Kanellias, Dimitrios Christoulas, Efstathios Kastritis, Meletios A Dimopoulos
Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra University Hospital, Athens, Greece
Abstract: Multiple myeloma remains an incurable disease despite the introduction of the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide and the proteasome inhibitor bortezomib that have improved the outcome of patients with both newly diagnosed and relapsed/refractory disease. However, patients who relapse after treatment with these agents or are refractory to them represent an unmet need and highlight the necessity for the development of novel anti-myeloma agents. Pomalidomide is an IMiD, structurally related to thalidomide, with enhanced antiangiogenic, antineoplastic, and anti-inflammatory properties and exhibiting potent anti-myeloma activity in vitro and in vivo. Pomalidomide has shown remarkable activity in patients who were refractory to both bortezomib and lenalidomide in Phase II and III studies. This paper reviews the chemistry and mechanisms of action of pomalidomide as well as all the available data from clinical trials on pomalidomide use in patients with refractory/relapsed multiple myeloma.
Keywords: immunomodulatory drugs, cereblon, angiogenesis, lenalidomide, refractory
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.